The Icahn School of Medicine at Mount Sinai has licensed its next-generation diagnostic test epigenetic/AI platform to GNOMX Corp. This new technology uses artificial intelligence (AI) and bioinformatic tools to identify changes in the environment that impact the activity of individual genes in immune cells. GNOMX will utilize this technology to develop tests for various infectious diseases, antibiotic sensitivity, prognosis, and post-infectious conditions. These tests can be quickly developed and provide results either at a central laboratory or at the point of care.
GNOMX initially plans to create differentiated epigenetic diagnostic tests for three diseases: post-COVID immune dysregulation (long COVID), acute Lyme disease, and sepsis with rapid antibiotic sensitivity guidance. Currently, there is no definitive diagnostic test or criteria for post-COVID immune dysregulation, leaving millions of patients and clinicians struggling with evaluations. Similarly, current tests for Lyme disease may miss a significant number of cases, leading to complications and high medical expenses. GNOMX diagnostics aim to address these challenges and provide accurate and specific information to guide treatment and reduce healthcare costs.
GNOMX Corp. was founded in October 2022 with the goal of improving health outcomes and reducing medical costs through the development of tests for infectious diseases and related conditions. The company is led by J. Mark Junewicz, Chief Executive Officer, and supported by Stuart Sealfon, MD, the scientific founder and Chief Scientific Officer. The epigenetic diagnostic technology being developed by GNOMX is part of a DARPA-funded research program led by Mount Sinai Health System. GNOMX’s advanced AI analytics capabilities and focus on epigenetics set them apart and make their tests more accurate and reliable.
Erik Lium, PhD, the Chief Commercial Innovation Officer of the Mount Sinai Health System and the President of MSIP, expressed excitement about collaborating with GNOMX on the development of this transformative technology. He looks forward to the launch of clinical epigenetic diagnostic and prognostic tests for emerging pathogens and related conditions.
The GNOMX epigenetic diagnostic platform includes technology developed by Mount Sinai faculty and has been licensed to GNOMX. Mount Sinai and its faculty members have a financial interest in this technology and in GNOMX. Felipe Araujo, PhD, of Mount Sinai serves on GNOMX’s Board of Directors as the Managing Director of Business Development and Licensing within MSIP.
About GNOMX Corp.
GNOMX Corp. (GNOMX) was founded in 2022 to commercialize host response epigenetic diagnostics based on research funded by the Defense Advanced Research Projects Agency (DARPA). The technology developed through this research program allows for the rapid diagnosis, determination of time of exposure, and monitoring of long-term effects of infections and other exposures. GNOMX executed an option with Mount Sinai for a worldwide license to this technology, which offers high-specificity, low cross-reactivity, and compatibility with rapid diagnostic assays.
About the Icahn School of Medicine at Mount Sinai
The Icahn School of Medicine at Mount Sinai is internationally renowned for its outstanding research, educational, and clinical care programs. As the academic partner for the Mount Sinai Health System, it provides care to a large and diverse patient population. The school ranks 14th nationwide in National Institutes of Health funding and has a talented faculty working across 34 academic departments and 35 multidisciplinary institutes. The focus is on translational research and therapeutics in various areas, including genomics, virology, neuroscience, cardiology, and gastrointestinal and liver diseases.
The school offers competitive MD, PhD, and master’s degree programs, with a large graduate medical education program and numerous postdoctoral research fellows. Situated in New York City on the border between the Upper East Side and East Harlem, the school benefits from its location and the opportunity to interact with diverse communities.
About Mount Sinai Innovation Partners
Mount Sinai Innovation Partners (MSIP) is responsible for advancing the application and commercialization of Mount Sinai discoveries and inventions. MSIP evaluates, patents, markets, and licenses new technologies, builds research collaborations and partnerships, and fosters an ecosystem of entrepreneurship. The aim is to translate discoveries and inventions into healthcare products and services that benefit patients and society.
Media Contact
Mount Sinai Press Office, Mount Sinai Health System, 212-241-9200, [email protected], www.mountsinai.org
SOURCE Icahn School of Medicine at Mount Sinai
